Expression of apoptosis-stimulating protein of p53 family members in invasive breast cancer and its prognostic significance

doi:10.3877/cma.j.issn.1674-0807.2020.01.011

Abstract

Abstract:

Objective

To explore the expression of apoptosis-stimulating protein of p53 (ASPP) family members in invasive breast cancer and their relationship with p53 expression, molecular subtype and prognosis of patients.

Methods

The tissue samples from 155 invasive breast cancer patients in the Department of Pathology, No. 989 Hospital of PLA from January 2005 to April 2010 were analyzed retrospectively. The expression of ASPP family members (ASPP1, ASPP2, iASPP), p53, ER, PR, HER-2 and Ki67 in breast cancer tissue samples was detected by immunohistochemistry. The relationship between the expression of ASPP family members and different molecular subtypes or p53 expression were analyzed by χ² test, and the Kaplan-Meier method was used to analyze the relationship between expression of ASPP family members and patient survival.

Results

In the invasive breast cancer tissue samples of 155 cases, the positive rate of ASPP1 was 13.5% (21/155), ASPP2 97.4% (151/155), and iASPP 61.3% (95/155). There were 33 cases of wild-type p53 expression and 122 cases of p53 mutation expression, so the mutation rate of p53 was 78.7% (122/155). There was no significant difference in the expression of ASPP family members between the wild-type p53 expression group and p53 mutation group (ASPP1: χ²<0.001, P=0.987; ASPP2: χ²=1.110, P=0.579; iASPP: χ²=0.244, P=0.621). There were 44 patients with luminal A subtype breast cancer, 66 luminal B, 18 basal-like and 27 HER-2 over-expression in all 155 patients, suggesting no significant difference in the expression of ASPP family members across different subtypes(ASPP1: χ²=2.325, P=0.508; ASPP2: χ²=1.657, P=0.642; iASPP: χ²=0.815, P=0.846). The patients were followed up for 2-108 months, median 66 months. The 3-year survival rate was 84.5% (131/155) and 5-year survival rate was 79.4% (123/155). There was no significant difference between ASPP1/ASPP2/iASPP positive group and negative group in the 5-year survival (ASPP1: χ²=3.790, P=0.050; ASPP2: χ²=0.040, P=0.927; iASPP: χ²=1.253, P=0.263).

Conclusions

The expression of ASPP family members in invasive breast cancer is not related to p53 mutation, molecular subtype and survival.

Key words: Breast neoplasms, Apoptosis, Molecular typing, Prognosis, Tumor suppressor protein p53

Wenfeng Ma, Hui Zhang, Naijun Fan, Fulin Li, Nianlong Meng, Xutao Yuan, Changsong Wang. Expression of apoptosis-stimulating protein of p53 family members in invasive breast cancer and its prognostic significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2020, 14(01): 44-49.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2020.01.011

https://zhrxbzz.cma-cmc.com.cn/EN/Y2020/V14/I01/44

Figures/Tables 8

References 18

[1]	Wang C, Gao C, Chen Y, et al. Expression pattern of the apoptosis-stimulating protein of p53 family in p53＋ human breast cancer cell lines [J]. Cancer Cell Int, 2013, 13(1)：116.
[2]	Xie XF, Yang Q, Chi J, et al. Prognostic values of apoptosis-stimulating P53-binding protein 1 and 2 and their relationships with clinical characteristics of esophageal squamous cell carcinoma patients: a retrospective study [J]. Chin J Cancer，2017, 36(1)：15.
[3]	Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level [J]．Int J Gynecol Pathol, 2004, 23(2): 129-137.
[4]	《乳腺癌HER2检测指南(2014版)》编写组．乳腺癌HER2检测指南(2014版)[J]．中华病理学杂志，2014，43(4)：262-267.
[5]	Gresham D. Cheating death [J]. Nat Rev Mol Cell Biol, 2003, 4(2)：87.
[6]	Liu ZJ，Lu X, Zhong S. ASPP-apoptotic specific regulator of p53 [J]. Biochim Biophys Acta, 2005, 1756(1)：77-80.
[7]	王长松，李红，高春芳，等. iASPP对表达野生型p53基因的乳腺癌细胞株MCF-7凋亡的影响[J]. 中国病理生理杂志， 2010，26(2): 282-286.
[8]	Qiu S, Cai Y, Gao X, et al. A small peptide derived from p53 linker region can resume the apoptotic activity of p53 by sequestering iASPP with p53 [J]. Cancer Lett, 2015，356 (2 Pt B): 910-917.
[9]	Li G，Wang R，Gao J，et al. RNA interference-mediated silencing of IASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in u251 human glioblastoma cells [J]. Mol Cell Biochem, 2011，350(1-2)：193-200.
[10]	Jia Y, Peng L, Rao Q, et al. Oncogene iASPP enhances self-renewal of hematopoietic stem cells and facilitates their resistance to chemotherapy and irradiation [J]. FASEB J, 2014, 28: 2816-2827.
[11]	Chan KK, Wong ES, Wong IT, et al. Overexpression of iASPP is required for autophagy in response to oxidative stress in choriocarcinoma [J]. BMC Cancer, 2019, 19(1)：953-965.
[12]	Robinson RA, Lu X, Jones EY, et al. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73 [J]. Structure, 2008, 16 (2)：259-268.
[13]	Wang Y, Godin-Heymann N, Dan Wang X, et al. ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells [J]. Cell Death Differ, 2013，20(4): 525-534.
[14]	Ao Y, Rohde LH, Naumovski L. P53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis [J]. Oncogen, 2001, 20 (21): 2720-2725.
[15]	Chikh A, Matin RN, Senatore V, et al. iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia [J]. EMBO J, 2011, 30(20)：4261-4273.
[16]	Lossos IS, Natkunam Y，Levy R, et al. Apoptosis stimulating protein of p53(ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma：corelation with clinical outcome [J]. Leuk Lympoma, 2002, 43(12)：2309-2317.
[17]	Pang Y, Pan L, Zhang Y, et al. TP53BP2 decreases cell proliferation and induces autophagy in neuroblastoma cell lines [J]. Oncol Lett, 2019，17(6): 4976-4984.
[18]	Kong F, Shi X, Li H, et al. Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection[J]. Am J Cancer Res, 2015, 5(3)：1217-1224.

Please choose a citation manager

Content to export